Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Tumor promoting properties of the ETS protein MEF in ovarian cancer

Oncogene volume 26, pages 4032–4037 (2007)Cite this article

Abstract

We have previously shown that MEF (myeloid ELF1-like factor, also known as ELF4) functions as a transcriptional activator of the interleukin (IL)-8, perforin, granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-3 genes in hematopoietic cells. MEF is also expressed in non-hematopoietic tissues including certain ovarian cancer cells. To define the function of MEF in these cells, we examined primary human ovarian epithelial tumors and found that MEF is expressed in a significant proportion of ovarian carcinomas, and in the CAOV3 and SKOV3 ovarian cancer cell lines, but not in normal ovarian surface epithelium. Manipulating MEF levels in these cell lines altered their behavior; reducing MEF levels, using short hairpin RNA expressing vectors, significantly inhibited the proliferation of SKOV3 and CAOV3 cells in culture, and impaired the anchorage-independent growth of CAOV3 cells. Overexpression of MEF in SKOV3 cells (via retroviral transduction) significantly increased their growth rate, enhanced colony formation in soft agar and promoted tumor formation in nude mice. The oncogenic activity of MEF was further shown by the ability of MEF to transform NIH3T3 cells, and induce their tumor formation in nude mice. MEF is an important regulator of the tumorigenic properties of ovarian cancer cells and could be used a therapeutic target in ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Aryee DN, Petermann R, Kos K, Henn T, Haas OA, Kovar H . (1998). Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its characterization and chromosomal assignment relative to ELF-1. Gene 210: 71–78.

    Article  CAS  Google Scholar 

  • Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E et al. (1997). Loss of heterozygosity at chromosome segment Xq25–26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer 20: 234–242.

    Article  CAS  Google Scholar 

  • Du Y, Spence SE, Jenkins NA, Copeland NG . (2005). Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 106: 2498–2505.

    Article  CAS  Google Scholar 

  • Fukushima T, Miyazaki Y, Tsushima H, Tsutsumi C, Taguchi J, Yoshida S et al. (2003). The level of MEF but not ELF-1 correlates with FAB subtype of acute myeloid leukemia and is low in good prognosis cases. Leuk Res 27: 387–392.

    Article  CAS  Google Scholar 

  • Hedvat CV, Yao J, Sokolic RA, Nimer SD . (2004). Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cells. J Biol Chem 279: 6395–6400.

    Article  CAS  Google Scholar 

  • Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J et al. (2002). The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 17: 437–449.

    Article  CAS  Google Scholar 

  • Lacorazza HD, Nimer SD . (2003). The emerging role of the myeloid Elf-1 like transcription factor in hematopoiesis. Blood Cells Mol Dis 31: 342–350.

    Article  CAS  Google Scholar 

  • Lacorazza HD, Yamada T, Liu Y, Miyata Y, Sivina M, Nunes J et al. (2006). The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells. Cancer Cell 9: 175–187.

    Article  CAS  Google Scholar 

  • Liu Y, Hedvat CV, Mao S, Zhu XH, Yao J, Nguyen H et al. (2006). The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol Cell Biol 26: 3114–3123.

    Article  CAS  Google Scholar 

  • Lund AH, Turner G, Trubetskoy A, Verhoeven E, Wientjens E, Hulsman D et al. (2002). Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 32: 160–165.

    Article  CAS  Google Scholar 

  • Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E et al. (2002). High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32: 153–159.

    Article  CAS  Google Scholar 

  • Milde-Langosch K, Hagen M, Bamberger AM, Loning T . (2003). Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2, in ovarian cancer. Int J Gynecol Pathol 22: 168–174.

    Article  Google Scholar 

  • Miyazaki Y, Boccuni P, Mao S, Zhang J, Erdjument-Bromage H, Tempst P et al. (2001). Cyclin A-dependent phosphorylation of the ETS-related protein, MEF, restricts its activity to the G1 phase of the cell cycle. J Biol Chem 276: 40528–40536.

    Article  CAS  Google Scholar 

  • Miyazaki Y, Sun X, Uchida H, Zhang J, Nimer S . (1996). MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene 13: 1721–1729.

    CAS  PubMed  Google Scholar 

  • Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama Y et al. (2002). The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res 62: 6579–6586.

    CAS  PubMed  Google Scholar 

  • Seth A, Watson DK . (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462–2478.

    Article  CAS  Google Scholar 

  • Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I . (2003). The significance of Elf-1 expression in epithelial ovarian carcinoma. Int J Mol Med 12: 349–354.

    CAS  PubMed  Google Scholar 

  • Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.

    Article  CAS  Google Scholar 

  • Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C et al. (2000). Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/ Akt pathway in human ovarian cancer. Oncogene 19: 2324–2330.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Irina Linkov and Marina Asherov from the Immunohistochemistry core laboratory of Memorial Sloan-Kettering Cancer Center for their assistance with immunohistochemical stains. The ϕ-A-MLV and pSRαMSVtkneo plasmids were kindly provided by Owen Witte. This work was supported by the National Heart, Lung, and Blood Institute Grant K08 HL4478 (CV Hedvat), National Cancer Institute Grant K01 CA099156 (HD Lacorazza) and the National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK052208 (SD Nimer), Ovarian Cancer PPG #CA052477 (SD Nimer) and the Produce A Cure Fund (SD Nimer).

Author information

Author notes

  1. H D Lacorazza

    Present address: Department of Pathology, Baylor College of Medicine, Houston, TX, USA

  2. J M Scandura

    Present address: Weill Medical College of Cornell University-New York Presbyterian Hospital, New York, NY, USA

Authors and Affiliations

  1. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    J J Yao, R A Soslow & C V Hedvat

  2. Laboratory of Molecular Aspects of Haematopoiesis, Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY, USA

    Y Liu, H D Lacorazza, J M Scandura, S D Nimer & C V Hedvat

  3. Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    J M Scandura & S D Nimer

Authors
  1. J J Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H D Lacorazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R A Soslow
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J M Scandura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S D Nimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C V Hedvat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S D Nimer.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yao, J., Liu, Y., Lacorazza, H. et al. Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene 26, 4032–4037 (2007). https://doi.org/10.1038/sj.onc.1210170

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210170

Keywords

This article is cited by

Search

Advanced search

Quick links